|
|
|
Congressional
Testimony
|
|
|
|
|
|
|
|
|
|
2002
December
- Janet Woodcock, M.D.
- December 11, 2002
Director, Center for Drug Evaluation and Research, Food and
Drug Administration before the Subcommittee on Oversight and
Investigations, Committee on Energy and Commerce, U.S. House
of Representatives.
- Karen Midthun,
M.D. - December 10, 2002
Director, Office of Vaccine Research and Review, Center for
Biologics Evaluation and Research Food and Drug Administration
Department of Health and Human Services before the Committee
on Government Reform U.S. House of Representatives.
November
- David W. Feigal, M.D.,
M.P.H. - November 14, 2002
Director, Center for Devices and Radiological Health
Food and Drug Administration, Department of Health and Human
Services before the Committee on Government Reform U.S. House
of Representatives.
October
- Lester M. Crawford,
D.V.M., Ph.D. - October 9, 2002
Deputy Commissioner, Food and Drug Administration, before
the Subcomittee on Health, Committee on Energy and Commerce,
House of Representatives.
- Lester M. Crawford,
D.V.M., Ph.D. - October 8, 2002, Deputy Commissioner,
Food and Drug Administration, before the Senate Subcommittee
on Oversight of Government Management, Restructuring and the
District of Columbia on the Regulatory Framework Under the
Dietary Supplement Health and Education Act.
- Jesse L.Goodman,
M.D., M.P.H. - October 3, 2002
Director, Deputy Director of the Center for Biologics Evaluation
and Research before the Subcommittee on Criminal Justice,
Drug Policy and Human ResourcesCommittee on Government on
FDA's Response to the Emerging Threat of West Nile Virus Reform
United States House of Representatives.
September
- Jesse Goodman, M.D.,
MPH, - September 24, 2002
Director, Deputy Director of the Center for Biologics
Evaluation and Research, to discuss FDA's response to the
emerging threat of transmission of West Nile virus (WNV) through
blood and tissue.
August
- Gary
Dykstra - August 5, 2002
Director, Southeast Regional Office, Office of Regulatory
Affairs, FDA's efforts to help ensure that FDA-regulated products
coming through the port of Tampa are safe and not used as
potential vehicles for terrorist acts while minimizing the
impact on the free flow of trade.
July
- Joseph A. Levitt
- July 31, 2002
Director, Center for Food Safety and Applied Nutrition, Food
and Drug Administration, Subcommittee on Oversight of Government
Management, Restructuring and the Dictrict of Columbia United
States Senate dietary supplements and their use for weight-loss
purposes.
- William K. Hubbard-
July 25, 2002
Senior Associate Commissioner, Policy, Planning and Legislation,
Food and Drug Administration, Subcommittee on Health, Committee
on Energy and Commerce, U.S. House of Representatives to discuss
concerns related to the importation of drugs into the United
States.
- William K. Hubbard-
July 9, 2002
Senior Associate Commissioner, Policy, Planning and Legislation,
Food and Drug Administration, Special
Committee on Aging, United States Senate to discuss concerns
related to the importation of drugs into the United States.
June
- Lester M. Crawford,
D.V.M., Ph.D. - June 12, 2002
Deputy Commissioner, Food and Drug Administration, Committee
on Governmental Affairs United States Senate to discuss the
shortages of childhood vaccines.
April
-
Lester M. Crawford, D.V.M., Ph.D. - April 30, 2002
Deputy Commissioner, Food and Drug Administration, Subcommittee
on Oversight of Government Management, Restructuring and the
District of Columbia discuss the safety of Federal school
lunches.
March
- Lester M. Crawford, D.V.M.,
Ph.D. - March 21, 2002
Deputy Commissioner, Food and Drug Administration, United
States House of Representatives Committee on Appropriations
to discuss FY 2003 budget.
- Lester M. Crawford, D.V.M.,
Ph.D. - March 6, 2002
Deputy Commissioner, Food and Drug Administration, Subcommittee
on Health Committee on Energy and Commerce Agency's success
in implementing the Prescription Drug User Fee Act and to
emphasize the importance of reauthorizing this law in advance
of its September 30, 2002, expiration date.
February
- Written Statement for
the Record regarding Mammography Quality Standards Act (MQSA)
of 1992. February 28, 2002
Subcommitte on Public Health Committee on Health, Education,
Labor, and Pensions -- Subcommittee on Labor, Health and Human
Services and Education Committee on Appropriations.
- John K. Jenkins,
M.D., February 12, 2002
Director, Office of New Drugs, CDER, Food and Drug Administration,
Committee on Health, Education, Labor, and Pensions to talk
about the drug OxyContin.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|